FDA: Page


  • Merck pays $625M to settle patent battle with Bristol, Ono

    In another twist to the two companies' rivalry, Merck will pay up to clear the patent dispute. 

    By • Jan. 23, 2017
  • Image attribution tooltip
    FDA
    Image attribution tooltip
    Deep Dive

    Biosimilars: What's in a name?

    The FDA recently finalized naming conventions for biosimilars, putting in place an important piece of the regulatory framework for the copycat biologics.

    By Ned Pagliarulo • Jan. 23, 2017
  • FDA gives go-ahead to Synergy's constipation drug

    Facing a crowded market, the company’s CEO asserts that Synergy has “the right strategic vision and the right launch plan” for Trulance.

    By Judy Packer-Tursman • Jan. 22, 2017
  • Prescribed Reading: A new era in pharma

    Trump is in, Califf is out, Bristol-Myers foregoes any possible lead in lung cancer and the FDA made its mark. 

    By Lisa LaMotta • Jan. 20, 2017
  • Bristol-Myers nixes hopes of early filing for Opdivo combo

    The pharma's shares tumbled by nearly 10% Friday morning on news it won't seek accelerated approval in first-line lung cancer for its Opdivo/Yervoy pairing. 

    By Ned Pagliarulo • Jan. 20, 2017
  • FDA details thinking on off-label communications

    The agency released two other draft guidance documents giving more clarity to the industry on medical product communications. 

    By Ned Pagliarulo • Jan. 19, 2017
  • McKesson Corp. pays $150M in record settlement with DOJ

    The federal government had alleged McKesson failed to report suspiciously large orders of controlled substances such as oxycodone and hydrocodone. 

    By Suzanne Elvidge • Jan. 19, 2017
  • Image attribution tooltip
    FDA
    Image attribution tooltip

    Chinese API supplier lands in hot water with FDA

    Suzhou Pharmaceuticals lacked a quality unit for starters, leading the FDA to ban the company from exporting to the U.S. 

    By Ned Pagliarulo • Jan. 18, 2017
  • FDA spells out expectations on biosimilar interchangeability

    Days after publishing guidance on biosimilar naming, the FDA is back at it again this week with important new recommendations on interchangeable biologic products. 

    By Ned Pagliarulo • Jan. 18, 2017
  • Image attribution tooltip
    FDA
    Image attribution tooltip

    FDA delays decision on Lilly and Incyte's arthritis drug

    Review of baricitinib will be extended by three months in order for the FDA to review new data submitted by Lilly. 

    By Suzanne Elvidge • Jan. 17, 2017
  • Tesaro plans speedy response to CRL for nausea drug

    The drugmaker disclosed last week the FDA had requested more details on manufacturing practices, an area where an increasing number of applications have fallen short. 

    By Suzanne Elvidge • Jan. 13, 2017
  • FDA issues long-awaited guidance on biosimilar naming

    With the biosimilar field set to grow dramatically, what to call the copycat drugs has been in debate.

    By Ned Pagliarulo • Jan. 12, 2017
  • JPM: Day 4 round-up

    A host of biotechs, including Novavax and MannKind, brought the huge healthcare conference to a close on Thursday.

    By Lisa LaMotta • Jan. 12, 2017
  • Prescribed Reading: Quiet before the storm

    M&A was slow in 2016 and 2017 is off to a slow start. But the JP Morgan conference in San Francisco next week could put dealmaking back in full swing. 

    By Lisa LaMotta • Jan. 6, 2017
  • FDA releases guidance on electronic drug applications

    The pharma industry may ditch paper drug applications sooner than it thinks, as the FDA pushes forward with a transition to electronic files.

    By • Jan. 5, 2017
  • Sanofi asked to pull vaccine ads in the Philippines

    The country's Food and Drug Administration called on the French pharma to pull radio and television ads for its Dengue fever vaccine, Dengvaxia.

    By • Jan. 4, 2017
  • After FDA delays pneumonia antibiotic, Cempra's shares plummet

    Some analysts contend the size and cost of the FDA's recommended safety study is impractical for the North Carolina-based biotech, likely sinking its lead product.

    By Judy Packer-Tursman • Dec. 30, 2016
  • Image attribution tooltip
    FDA
    Image attribution tooltip

    Biogen, Ionis gifted with approval for SMA drug

    The FDA okayed the first SMA drug months ahead of its PDUFA date. 

    By Lisa LaMotta • Dec. 26, 2016
  • A look back: Top stories of 2016

    2016 was a rollercoaster year full of clinical jackpots and busts, reorganizations, and dramatic economic and political twists. Here are some of the biggest headlines from the last 12 months.

    By • Dec. 26, 2016
  • Prescribed Reading: An uptick in year-end M&A

    Several companies are striking deals to round out the year, while others are trying to bury bad data, and the FDA cracks down on manufacturing. 

    By Lisa LaMotta • Dec. 23, 2016
  • Teva pays up $520M to settle bribery charges

    The Israeli generic drugmaker admitted to bribing foreign government officials in Russia, Ukraine and Mexico in a past effort to boost sales.

    By Ned Pagliarulo • Dec. 22, 2016
  • FDA warns drugmakers on misleading marketing

    Two companies were hit with warning letters last week for failing to disclose risks associated with their respective drugs.

    By Ned Pagliarulo • Dec. 21, 2016
  • FDA pushes decision on Roche MS drug to March

    Ocrevus would be the first to treat one type of the disease, and would help keep Roche's portfolio fresh amid patent expirations.

    By • Dec. 21, 2016
  • Image attribution tooltip
    FDA
    Image attribution tooltip

    Clovis lands early FDA OK for rucaparib

    Approval of the biotech's advanced ovarian cancer drug helps take the sting off a costly regulatory setback earlier this year. 

    By Suzanne Elvidge • Dec. 20, 2016
  • ADA guidelines highlight new Jardiance label

    Inclusion in the guidelines will provide a competitive advantage in a crowded market.

    By Suzanne Elvidge • Dec. 19, 2016